Riccardo Torta1, Ilaria Siri, Paola Caldera. 1. SCDU Psicologia Clinica e Oncologica, Ospedale San Giovanni Battista di Torino, corso Bramante 86/88, cap 10126, Turin, Italy. riccardo.torta@unito.it
Abstract
GOALS OF WORK: Cancer is often burdened by psychological comorbidity, mainly represented by depression, anxiety and adjustment disorders. Efficacy and tolerability of sertraline in the treatment of depressive disorders is well known; however, its efficacy and safety in patients with cancer has been poorly studied. This study was aimed to provide evidences of effectiveness, safety, tolerability and rapidity of action of sertraline in a population of oncological outpatients affected by mood disorders and its effects on quality of life. MATERIALS AND METHODS: Thirty-five adult cancer outpatients with mood depression, during chemotherapy, were enrolled to a 12-week trial with a flexible dose regime of sertraline. The treatment response was assessed at baseline, week 4 and week 12, with hospital anxiety and depression scale (HADS) and Montgomery Asberg depression rating scale (MADRS), to rate depression and anxiety; mini mental adjustment to cancer scale (Mini-MAC), to assess the psychological response to the diagnosis of cancer; clinical global impression (CGI) to evaluate severity of illness; dosage record and treatment emergent symptom scale (DOTES), to assess the adverse effects of the clinical treatments and their possible relation with the drug used; and QL index to rate quality of life. MAIN RESULTS: Both mean depression scores, analysed by HADS and MADRS scales, and HADS anxiety scores significantly decreased during the 12 weeks of study. Mean MINI-MAC scores show that hopelessness and anxious preoccupation decreased significantly at T2 compared with T0. No severe adverse effects were observed. CONCLUSION: In this preliminary study, sertraline was found to be effective and well tolerated in the treatment of depressed outpatients with cancer.
GOALS OF WORK: Cancer is often burdened by psychological comorbidity, mainly represented by depression, anxiety and adjustment disorders. Efficacy and tolerability of sertraline in the treatment of depressive disorders is well known; however, its efficacy and safety in patients with cancer has been poorly studied. This study was aimed to provide evidences of effectiveness, safety, tolerability and rapidity of action of sertraline in a population of oncological outpatients affected by mood disorders and its effects on quality of life. MATERIALS AND METHODS: Thirty-five adult cancer outpatients with mood depression, during chemotherapy, were enrolled to a 12-week trial with a flexible dose regime of sertraline. The treatment response was assessed at baseline, week 4 and week 12, with hospital anxiety and depression scale (HADS) and Montgomery Asberg depression rating scale (MADRS), to rate depression and anxiety; mini mental adjustment to cancer scale (Mini-MAC), to assess the psychological response to the diagnosis of cancer; clinical global impression (CGI) to evaluate severity of illness; dosage record and treatment emergent symptom scale (DOTES), to assess the adverse effects of the clinical treatments and their possible relation with the drug used; and QL index to rate quality of life. MAIN RESULTS: Both mean depression scores, analysed by HADS and MADRS scales, and HADS anxiety scores significantly decreased during the 12 weeks of study. Mean MINI-MAC scores show that hopelessness and anxious preoccupation decreased significantly at T2 compared with T0. No severe adverse effects were observed. CONCLUSION: In this preliminary study, sertraline was found to be effective and well tolerated in the treatment of depressed outpatients with cancer.
Authors: D Razavi; J F Allilaire; M Smith; A Salimpour; M Verra; B Desclaux; P Saltel; I Piollet; A Gauvain-Piquard; C Trichard; B Cordier; R Fresco; E Guillibert; D Sechter; J P Orth; M Bouhassira; P Mesters; P Blin Journal: Acta Psychiatr Scand Date: 1996-09 Impact factor: 6.392
Authors: Javaid I Sheikh; Erin L Cassidy; P Murali Doraiswamy; Ronald M Salomon; Mady Hornig; Peter J Holland; Francine S Mandel; Cathryn M Clary; Tal Burt Journal: J Am Geriatr Soc Date: 2004-01 Impact factor: 5.562
Authors: Joseph A Roscoe; Gary R Morrow; Jane T Hickok; Karen M Mustian; Jennifer J Griggs; Sara E Matteson; Peter Bushunow; Raman Qazi; Brian Smith Journal: Breast Cancer Res Treat Date: 2005-02 Impact factor: 4.872
Authors: Laura Amodeo; Lorys Castelli; Paolo Leombruni; Daniela Cipriani; Alessia Biancofiore; Riccardo Torta Journal: Support Care Cancer Date: 2011-03-15 Impact factor: 3.603
Authors: Erik E Rabin; Miri Kim; Andreas Mozny; Krislyn Cardoza; April C Bell; Lijie Zhai; Prashant Bommi; Kristen L Lauing; Amanda L King; Terri S Armstrong; Theresa L Walunas; Deyu Fang; Ishan Roy; John D Peipert; Erica Sieg; Xinlei Mi; Christina Amidei; Rimas V Lukas; Derek A Wainwright Journal: Brain Behav Immun Health Date: 2022-03-23